For weaned piglets transitioning from sow milk to solid feed, gastric stasis and incomplete feed digestion are managed on production farms by dispersing Jianwei Xiaoji Powder veterinary-grade API into oral granule intermediates. The API is released against the Chinese Veterinary Pharmacopoeia 2020 monograph for Jianwei Xiaoji San, with residual solvent evaluation aligned to VICH GL18 and granulation operations conducted under EU GMP Part II conditions. In this downstream segment, the API is incorporated at 8.0–15.0 wt% of the final granule dry matter, equivalent to 800–1500 g of API per 10 kg batch before drying. Dry blending with maize starch and low-viscosity hydroxypropyl methylcellulose binder at 2.0–4.0 wt% is carried out in a high-shear mixer at 150–300 rpm for 3–5 min, followed by wet massing at 8.0–12.0% water addition, extrusion through a 0.8 mm screen, and fluid-bed drying at inlet air temperature 50–60°C to final moisture <3.0%. The dried granule is sized with a 0.250 mm and 0.850 mm sieve stack before filling into 100 g and 1 kg low-density polyethylene sachets. The terminal product is an oral granule for weaned piglets, with batch-to-batch particle size distribution monitored because source herb starch content shifts under different harvest seasons.

What Limits Compression Hardness in Multi-Herb Veterinary Tablets?

During rotary compression of multi-herb powders, the dominant constraint is not active potency loss but hygroscopic extract softening, which increases tablet sticking and capping at ambient relative humidity above 60%. Tablet release is anchored to USP <905> content uniformity, Pharmacopoeia Europe 2.9.5 uniformity of mass, and Pharmacopoeia Europe 2.9.8 friability, while the tableting suite maintains 21 CFR 210/211 veterinary finished drug GMP documentation and EU GMP Annex 15 validation of critical equipment. The API inclusion is 20.0–35.0 wt% of the tablet core; for a 500 mg tablet, active extract mass therefore ranges from 100–175 mg. The API is pre-dried at 45–55°C to moisture <3.0%, then blended in a twin-shell V-blender at 12–15 rpm for 15–20 min with microcrystalline cellulose, dicalcium phosphate dihydrate, crospovidone, colloidal silicon dioxide, and magnesium stearate. Final compression is performed on a 16-station D-tooling rotary tablet press at 8–15 kN compression force, with target hardness 70–100 N and friability <1.0%. The terminal product is a scored 500 mg oral tablet for calves and adult cattle. Compression runs are restricted when the API retains more than 3.0% residual moisture because extract particles adhere to punch faces; anti-adherent magnesium stearate is held at 0.5–1.5 wt% to avoid excessive film formation that retards disintegration.

Aseptic manufacture of Jianwei Xiaoji Powder veterinary-grade API into injectable solutions is constrained by plant-derived polysaccharides with thermal-labile glycosidic bonds, making terminal sterilisation at 121°C for 15 min a high-risk unit operation that can produce insoluble precipitates and pH drift. The solution is compounded in a Grade C background with Grade A laminar-airflow protection; sterility assurance follows Pharmacopoeia Europe 5.1.1 and EU GMP Annex 1, and container closure integrity is verified by dye ingress according to USP <1207>. The API is dissolved at an active concentration equivalent to 5.0–20.0 g of crude Jianwei Xiaoji Powder per 100 mL of solution, dependent on species and approved label claim. Purified water or water for injection is heated to 35–40°C to aid dispersion without triggering polysaccharide chain scission, then pH adjusted to 5.5–6.5. The solution is clarified through a 0.45 µm capsule and sterilized through a 0.22 µm PVDF membrane at differential pressure <1.0 bar, followed by filling into 50 mL Type II glass vials on a peristaltic pump line at 20–30 vials/min. The terminal product is a 50 mL multi-dose injectable solution for swine and cattle. Published data for this specific API at production-scale injectable filling is limited; therefore, the filtration boundary is derived from multi-herb extract behaviour and is not a substitute for process validation. The formulation should not be combined with hypertonic electrolyte diluents above 0.9% sodium chloride because salting-out of the polysaccharide fraction can occur during line stoppages.

Water Distribution Systems Clog When Unscreened Particles Exceed 75 µm

In commercial poultry houses, the limiting failure mode is not dissolution rate but sedimentation and nozzle fouling in closed drinking-water lines where pipeline pressure fluctuates. The finished water-dispersible powder is released under national veterinary drug GMP provisions such as 21 CFR 210/211, with feed-safety controls under ISO 22000 and HACCP documentation for cross-contamination prevention; regional withdrawal periods are governed by the approved veterinary medicinal product registration rather than feed additive law. API loading in the finished powder is 50.0–70.0 wt%; in drinking-water stock solution, the working concentration is 0.5–2.0 g of API powder per litre of drinking water, mixed in a bulk tank before delivery to nipple drinkers. The API is co-milled with anhydrous lactose and citric acid through a 0.75 mm mesh, with milled particle size controlled below 75 µm to prevent nozzle occlusion. Blending is performed in a ribbon mixer at 20 rpm for 10 min, and the output is filled into 1 kg foil laminate pouches as a water-dispersible powder for poultry drinking water. Hard water above 200 mg/L calcium carbonate equivalence may reduce hydrosolubility; a citric acid buffer at 1.0 g/L is therefore included when field water analysis indicates carbonate hardness above this threshold. Stock solutions must be consumed or replaced within 24 h because reconstituted herbal polysaccharide solutions are susceptible to microbial growth in warm poultry house environments.

Pre-blend Carrier Selection and Segregation Thresholds in Medicated Feed Premix

In beef and dairy feed mills, the transition from medicated oral powder to feed premix imposes a different set of constraints: carrier absorbency, particle size ratio, dust-off at the mixer discharger, and carryover into non-medicated batches. Premix production falls under 21 CFR Part 225 current good manufacturing practice for medicated feeds, (EU) 2019/4 for medicated feed manufacture and use, and ISO 22000 feed safety management. The API is pre-diluted in a fumed silica and corn cob carrier at 5.0–25.0 wt%; final feed inclusion is 2.0–5.0 kg of active premix per 1000 kg complete feed. A horizontal paddle mixer operating at 15–20 rpm with 60–70% fill level is used to blend the pre-diluted API into the main ration for 10–12 min after main component addition; sequential flushing with 1.0 kg calcium carbonate per 100 kg mixer capacity is applied to control carryover. The terminal product is a 20 kg paper bag with polyethylene inner liner, labelled as a medicated feed premix for ruminants. Molasses-coated carriers should be avoided because residual reducing sugars and moisture promote extract particle cohesion and bin discharge blockages. If the API-to-carrier particle size ratio exceeds 3:1, segregation is likely during screw conveying; 0.5 wt% vegetable oil may be added to suppress dust without converting the blend into a paste.

When Feline and Canine Digestive Support Moves into Two-Piece Gelatin Capsules

For companion animal dose forms, the low-dose precision requirement changes the critical control point from mixer segregation to encapsulation tamping-pin compaction ratio and fill moisture management. Capsule filling is verified against USP <905> content uniformity and Pharmacopoeia Europe 2.9.5 uniformity of mass, with gelatin capsule dissolution tested according to USP <711> using purified water at 37±0.5°C. API loading in each two-piece gelatin capsule is 30.0–60.0 wt% of the fill mass; for a 250 mg capsule, active extract mass ranges from 75–150 mg. The API is blended with pre-gelatinized starch and colloidal silicon dioxide, and the final blend moisture is controlled below 4.0% before filling. A dosator or tamping pin capsule filler operating at 10,000–30,000 capsules/h is used, with pin compaction penetration set at 3–5 mm to prevent bridges without causing tamping-pin overload. Filled capsules are packaged with desiccant in aluminium/PVC blisters to maintain in-pack humidity below 35% at 25°C. The terminal product is a 250 mg two-piece gelatin capsule for feline and canine digestive support. Capsule suite relative humidity is maintained at 35–45% because hygroscopic fill powder above this range softens gelatin shells and can cause telescoping on the filling line, while moisture below 30% increases static charge and weight variation.